Efficient Clinical Programs and Decision Making Through Model-Informed Drug Development (MIDD)
Efficient Clinical Programs and Decision Making Through Model-Informed Drug Development (MIDD) Join Alex MacDonald, VP Model-Informed Drug Development, on how MIDD can help your clinical trials.
Pediatric Clinical Trials: Tackling Clinical and Therapeutic Development Challenges Head-On
There remains a crucial need to include children in clinical development as historically they have been underrepresented in clinical trials. This is due to the complexities of including children, their vulnerabilities and the lack of motivation for drug developers to pursue marketing authorization for pediatric populations. These challenges faced in developing pediatric medicine are not […]
More than Skin Deep: Considerations for Dermatology and Drugs Administered to the Skin
PBPK Modeling for Pediatric Drug Development
Watch to learn more from our A-Team on PBPK modeling for pediatric drug development. https://www.youtube.com/watch?v=GWP4bSn4W0Y
Benefits of Bayesian Dose Escalation Designs for Oncology Studies
As acceptance of flexible trial designs continues to advance, many sponsors are increasingly exploring alternate methods for dose escalation to support identification of a maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) in open-label Early Phase or First in Human studies. Bayesian dose escalation designs have also coincided with advances in oncology therapy […]
Risk Assessment: Traditional and Novel Approaches to Assess and Manage Risks
Risk assessment is a complex process intended to protect human health by identifying drug-related hazards, determining dose-response relations for a product within relevant biological systems, and assessing exposure levels to characterize potential risks. These assessments may be conducted via traditional frameworks using data from in vitro and in vivo studies, as well as novel frameworks using pharmacokinetic and pharmacodynamic model-based […]
Inspection Readiness: What is it, why it matters, and what you need to know to be prepared
Organizations must have inspection readiness since inspections can be unannounced or come at any time. Good Clinical Practice (GCP) inspectors use different approaches depending on the regulatory authorities for which they represent; however, all of them will verify the compliance status on GCP and other applicable regulations during the inspection. Planning ahead to anticipate all processes are compliant means an organization […]
Navigating Regulatory Strategies for Cellular & Gene Therapies
While any drug development program can face regulatory hurdles, developing cellular and gene therapies often presents unique challenges. Small and midsize biotech and pharma companies developing cellular and gene therapies should begin to understand critical nuances for successful regulatory meetings and submissions and how they impact strategic decisions during the product development lifecycle. At the […]
Roadmap To Marketing Authorisation in Europe: Taking All the Right Turns
Approval of your Marketing Authorisation Application (MAA) is the final hurdle to pharmaceutical product launch in Europe. Adequate and timely navigation of this roadmap is essential to achieve a successful review by the EMA. Navigation of the drug development pathways towards MAA approval starts much earlier than you may know till date and is essential […]
Webinar | Pharmacogenomics and Pediatric Drug Development: When Are Children Not Little Adults and Why?
This webinar covers an introduction of the intersection of ontogeny and pharmacogenomics as it relates to differences in drug biotransformation and pharmacokinetics in pediatrics. At the end of this webinar, attendees should have a better understanding of: The concept of “developmental trajectory” in the context of drug biotransformation How ontogeny and pharmacogenomics contribute to variability […]